Cargando…

Comparison of the effect of lemborexant and other insomnia treatments on driving performance: a systematic review and meta-analysis

STUDY OBJECTIVES: This systematic literature review and meta-analysis explored the impact of lemborexant and other insomnia treatments on next-day driving performance. METHODS: Searches were conducted in MEDLINE and Embase on May 16, 2019, supplemented by clinical trial registries. Randomized contro...

Descripción completa

Detalles Bibliográficos
Autores principales:	McElroy, Heather, O’Leary, Beth, Adena, Michael, Campbell, Renee, Tahami Monfared, Amir Abbas, Meier, Genevieve
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10104353/ https://www.ncbi.nlm.nih.gov/pubmed/37193564 http://dx.doi.org/10.1093/sleepadvances/zpab010

Ejemplares similares

Comparative efficacy of lemborexant and other insomnia treatments: a network meta-analysis
por: McElroy, Heather, et al.
Publicado: (2021)

Lemborexant for insomnia
Publicado: (2021)

The effect of lemborexant for insomnia disorder
por: Suzuki, Hidenobu, et al.
Publicado: (2021)

Pilot Study of Lemborexant for Insomnia in Cancer Patients with Delirium
por: Terada, Tatsuto, et al.
Publicado: (2022)

Efficacy and safety of lemborexant in midlife women with insomnia disorder
por: Terauchi, Masakazu, et al.
Publicado: (2023)

PSUN201 Efficacy and Safety of Lemborexant in Diabetic Patients With Insomnia Disorder
por: Moline, Margaret, et al.
Publicado: (2022)

Efficacy and safety of lemborexant over 12 months in Asian adults with insomnia disorder
por: Dash, Amitabh, et al.
Publicado: (2022)

Burden of Disease and Current Management of Dementia with Lewy Bodies: A Literature Review
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2019)

On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers
por: Vermeeren, Annemiek, et al.
Publicado: (2018)

Erratum to: On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers
por: Vermeeren, Annemiek, et al.
Publicado: (2020)

P096 Subjective ratings of medication strength of lemborexant over 6 months in subjects with moderate or severe insomnia
por: Drake, C, et al.
Publicado: (2021)

Assessment of morning sleep propensity with lemborexant in adults with insomnia disorder in a randomized, placebo-controlled crossover study
por: Mayleben, David, et al.
Publicado: (2021)

Factors Driving the Transition of Alzheimer’s Disease Patients to Institutional Long-term Care
por: Davila, Heather, et al.
Publicado: (2021)

P097 Incidence of abnormal dreams and nightmares with lemborexant in adults with insomnia: results from two Phase 3 studies
por: Roth, T, et al.
Publicado: (2021)

Effect of discontinuation of lemborexant following long‐term treatment of insomnia disorder: Secondary analysis of a randomized clinical trial
por: Takaesu, Yoshikazu, et al.
Publicado: (2023)

Dual orexin receptor antagonists for treatment of insomnia: A systematic review and meta-analysis on randomized, double-blind, placebo-controlled trials of suvorexant and lemborexant
por: Khazaie, Habibolah, et al.
Publicado: (2022)

Can Lemborexant for Insomnia Prevent Delirium in High-Risk Patients with Pancreato-Biliary Disease after Endoscopic Procedures under Deep Sedation?
por: Ogura, Takeshi, et al.
Publicado: (2022)

Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant
por: Dayal, Satish, et al.
Publicado: (2021)

Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial
por: Rosenberg, Russell, et al.
Publicado: (2019)

Population Pharmacokinetics and Exposure‐Response Analyses for the Most Frequent Adverse Events Following Treatment With Lemborexant, an Orexin Receptor Antagonist, in Subjects With Insomnia Disorder
por: Lalovic, Bojan, et al.
Publicado: (2020)

Effect of gastric acid‐reducing agents on the pharmacokinetics and efficacy of lemborexant
por: Landry, Ishani, et al.
Publicado: (2020)

Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant
por: Landry, Ishani, et al.
Publicado: (2021)

Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2
por: Kärppä, Mikko, et al.
Publicado: (2020)

Cost-effectiveness analysis of lemborexant for treating insomnia in Japan: a model-based projection, incorporating the risk of falls, motor vehicle collisions, and workplace accidents
por: Ikeda, Shunya, et al.
Publicado: (2022)

Staging Disease Severity Using the Alzheimer’s Disease Composite Score (ADCOMS): A Retrospective Data Analysis
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2022)

Correction to: Staging Disease Severity Using the Alzheimer’s Disease Composite Score (ADCOMS): A Retrospective Data Analysis
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2022)

Cost-effectiveness analysis of lemborexant for treating insomnia in Japan: A model-based projection, incorporating the risk of falls, motor vehicle collisions, and workplace accidents – CORRIGENDUM
por: Ikeda, Shunya, et al.
Publicado: (2022)

Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada
por: Quon, Peter L., et al.
Publicado: (2019)

Characteristics of patients who were able to switch from benzodiazepine hypnotics to lemborexant
por: Suzuki, Hidenobu, et al.
Publicado: (2021)

Alzheimer’s Disease: Epidemiology and Clinical Progression
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2022)

Long-Term Health Outcomes of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2022)

The Humanistic and Economic Burden of Alzheimer's Disease
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2022)

The Potential Economic Value of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2022)

Understanding Barriers Along the Patient Journey in Alzheimer’s Disease Using Social Media Data
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2023)

Indirect treatment comparisons including network meta-analysis: Lenvatinib plus everolimus for the second-line treatment of advanced/metastatic renal cell carcinoma
por: Tremblay, Gabriel, et al.
Publicado: (2019)

Assessing the Clinical Meaningfulness of the Alzheimer’s Disease Composite Score (ADCOMS) Tool
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2022)

Physiologically‐based pharmacokinetic modeling to predict drug interactions of lemborexant with CYP3A inhibitors
por: Ueno, Takashi, et al.
Publicado: (2021)

A Simulation Model to Evaluate the Potential Impact of Disease-Modifying Treatments on Burden of Illness in Alzheimer’s Disease
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2022)

Clinical and Scientific Challenges to Effectiveness Studies Under Coverage with Evidence Development in Alzheimer’s Disease
por: Morin, Peter J., et al.
Publicado: (2023)

FLUID study: study protocol for an open-label, single-centre pilot study to investigate the efFect of Lemborexant on sleep management in Japanese sUbjects aged 50 years and older with Insomnia Disorder
por: Okada, Ippei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mu1p9p12vv3abi49367ail26pe